Versant Venture Capital VI, L.P. - Jun 28, 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
10%+ Owner
Signature
Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC By: /s/ Robin L. Praeger Its: Managing Director
Stock symbol
GLUE
Transactions as of
Jun 28, 2021
Transactions value $
$3,000,005
Form type
4
Date filed
6/30/2021, 05:00 PM
Previous filing
Jul 6, 2021
Next filing
Jul 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GLUE Common Stock Conversion of derivative security +6.52M +2300.43% 6.8M Jun 28, 2021 Direct F1, F2
transaction GLUE Common Stock Conversion of derivative security +1.94M 1.94M Jun 28, 2021 By Versant Vantage I, L.P. F1, F3
transaction GLUE Common Stock Purchase $3M +158K +8.14% $19.00 2.1M Jun 28, 2021 By Versant Vantage I, L.P. F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Series A convertible preferred stock Conversion of derivative security -20M -100% 0 Jun 28, 2021 Common Stock 5.67M Direct F1, F2
transaction GLUE Series B convertible preferred stock Conversion of derivative security -3M -100% 0 Jun 28, 2021 Common Stock 850K Direct F1, F2
transaction GLUE Series B convertible preferred stock Conversion of derivative security -4.15M -100% 0 Jun 28, 2021 Common Stock 1.18M By Versant Vantage I, L.P. F1, F3
transaction GLUE Series C convertible preferred stock Conversion of derivative security -2.7M -100% 0 Jun 28, 2021 Common Stock 765K By Versant Vantage I, L.P. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2 Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. Each of Versant Ventures VI GP, Versant Ventures VI GP-GP and Bradley J. Bolzon disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports
F3 Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. Each of Versant Vantage I GP, Versant Vantage I GP-GP and Bradley J. Bolzon disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports.